Global Blood Cancer Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Blood Cancer Therapeutics Market was valued at $77.1 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 10.0% CAGR, to an estimated market size of $124 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global blood cancer therapeutics market encompasses the development, production, and administration of pharmaceutical and biological treatments for hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. The scope includes targeted therapies, immunotherapies, chemotherapy, and stem cell transplant protocols, while excluding general surgical oncology and non-specific supportive care.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Blood Cancer Therapeutics Market in the period 2025-30:
- The market is shifting from conventional cytotoxic chemotherapy toward precision oncology and targeted therapies that minimize systemic toxicity.
- The rapid adoption of CAR-T cell therapies and bispecific antibodies is revolutionizing treatment outcomes for relapsed and refractory hematologic malignancies.
- Integration of AI-driven diagnostics and next-generation sequencing is enabling more accurate molecular profiling and personalized medicine approaches.
- Clinicians are increasingly utilizing combination therapies that pair immunotherapies with small-molecule inhibitors to overcome drug resistance.
- There is a significant trend toward oral formulations of oncology drugs to improve patient compliance and reduce the burden on hospital infrastructure.
- The emergence of biosimilars is expected to lower the overall cost of treatment and increase therapeutic accessibility in emerging markets.
- Regulatory bodies are providing accelerated approval pathways and orphan drug designations to expedite the commercialization of novel blood cancer treatments.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- South America
Segments
- Leukemia
- Lymphoma
- Multiple Myeloma
- Rare Blood Disorders